Comparative Pharmacology
Head-to-head clinical analysis: ALPHAZINE versus INAPSINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHAZINE versus INAPSINE.
ALPHAZINE vs INAPSINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-2 adrenergic receptor agonist in the central nervous system, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and heart rate.
Butyrophenone antipsychotic; antagonizes dopamine D2 receptors in the CNS, also exhibits alpha-adrenergic blocking activity.
Adults: IM/SC 10 mg every 4 hours as needed, maximum 40 mg/day; IV 5 mg over 1 minute, may repeat in 20-30 minutes, maximum 10 mg.
IM: 2.5-10 mg every 3-4 hours as needed; IV: 2.5-10 mg slow IV push (over 2-3 minutes), repeat every 30-60 minutes as needed; maximum total dose 20 mg.
None Documented
None Documented
5-7 hours; prolonged to 10-15 hours in renal impairment.
Terminal elimination half-life is 10-22 hours (mean 14.5 hours) in adults; may be prolonged in elderly or patients with hepatic impairment.
Primarily renal (60-70% unchanged), 20-30% biliary/fecal as metabolites.
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal excretion accounts for approximately 20-30%.
Category C
Category C
Antipsychotic
Antipsychotic